Skip to main content

Oxurion Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume1,467 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TBGNF News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxurion and its competitors with MarketBeat's FREE daily newsletter.

Oxurion logo

About Oxurion

Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally. Its lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of DME that has completed phase 1 clinical trial; THR-687 an integrin antagonist to treat patients with a diabetic eye disease that has completed phase 1 clinical trial; and TB-403, an anti- placental growth factor for the treatment of medulloblastoma, a pediatric malignant brain tumor. It has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Parexel, INC Research, and Galapagos. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.


Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
January 20, 2021 |
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Phone32 1 675 13 10
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.52 out of 5 stars

Medical Sector

1524th out of 2,044 stocks

Biotechnology Industry

87th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Oxurion (OTCMKTS:TBGNF) Frequently Asked Questions

What stocks does MarketBeat like better than Oxurion?

Wall Street analysts have given Oxurion a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oxurion wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Oxurion's stock been impacted by COVID-19 (Coronavirus)?

Oxurion's stock was trading at $3.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TBGNF shares have decreased by 15.8% and is now trading at $2.94.
View which stocks have been most impacted by COVID-19

Who are Oxurion's key executives?

Oxurion's management team includes the following people:
  • Dr. Patrik De Haes, CEO & Exec. Director
  • Mr. Thomas Graney, Chief Financial Officer (Age 56)
  • Prof. Alan Stitt Ph.D., Chief Scientific Officer
  • Mr. Wouter Piepers, Global Head of Corp. Communications & Investor Relations
  • Julie Binon, Head of HR
  • Dr. Andy De Deene, Global Head of Devel.
  • Mr. Ove Pedersen, Head of Product Supply (Age 64)
  • Marc Denayer, Global Head of Drug Safety & Medical Affairs
  • Ms. Vinciane Vangeersdaele, Chief Commercial Officer
  • Dr. Grace Chang M.D., Ph.D., Chief Medical Officer

Who are some of Oxurion's key competitors?

What is Oxurion's stock symbol?

Oxurion trades on the OTCMKTS under the ticker symbol "TBGNF."

How do I buy shares of Oxurion?

Shares of TBGNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oxurion's stock price today?

One share of TBGNF stock can currently be purchased for approximately $2.94.

How many employees does Oxurion have?

Oxurion employs 66 workers across the globe.

What is Oxurion's official website?

The official website for Oxurion is

How can I contact Oxurion?

The company can be reached via phone at 32 1 675 13 10.

This page was last updated on 5/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.